logo

Assembly Biosciences, Inc. (ASMB)



Trade ASMB now with
  Date
  Headline
6/27/2019 7:13:08 AM Assembly Biosciences Announces First Patient Dosed With ABI-M201 In Phase 1b Clinical Trial
1/7/2019 7:12:46 AM Assembly Biosciences Completes Patient Enrollment In Two Phase 2a Studies With ABI-H0731
11/12/2018 7:06:04 AM Assembly Biosciences Presents Final Results Of Phase 1b Study Of ABI-H0731 At 2018 AASLD
11/8/2018 7:21:48 AM Assembly Biosciences Q3 Loss Per Share $0.87 Vs Loss $0.71 Last Year
7/25/2018 7:14:04 AM Assembly Biosciences Says FDA Fast Track Designation Granted To ABI-H0731 For Treatment Of Hepatitis B Virus
7/10/2018 4:04:47 PM Assembly Biosciences Announces Proposed Underwritten Offering Of Common Stock
7/9/2018 7:06:53 AM Assembly Biosciences Initiates Two Phase 2a Trials Of ABI-H0731 For Hepatitis B Virus Infection
6/8/2018 7:08:26 AM Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4/12/2018 3:17:16 AM Assembly Biosciences Presents Positive Interim Data From Phase 1a And 1b Studies Of ABI-H0731 In HBV Patients
4/2/2018 4:56:56 PM Assembly Biosciences Appoints Jackie Papkoff As SVP, Chief Scientific Officer
3/28/2018 5:35:52 AM Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted As A Late-Breaker Poster At EASL
3/12/2018 7:09:46 AM Assembly Biosciences Appoints Graham Cooper As CFO And COO And Helen To Board
1/5/2018 1:21:53 PM B. Riley FBR Starts ASSEMBLY BIOSCIENCES, INC. (ASMB) At Buy With $35.00 Price Target